Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071331 · ClinicalTrials.gov registry record · Phase 3
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,600
- Enrollment target
NCT00071331: Completed Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00071331 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 3,600 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (366% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00071331, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,600 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
Interventions
- DRUG Tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,600 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00071331 record still lists
NCT00071331 is an interventional study that assigns participants to a tested intervention. Its 3,600 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (366% higher).
The record links to 0 conditions, and to 1 intervention - of which Tolvaptan is the first listed.
NCT00071331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00071331 about?
NCT00071331 is a clinical study titled "EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan". The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
What is the current status of trial NCT00071331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,600 participants. The study started on 2003-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00071331?
The interventions under investigation include: Tolvaptan (DRUG).
Who is sponsoring clinical trial NCT00071331?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00071331's enrollment target sits among peer trials
3,600 68th of 2000 higher than 1,933 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
- NCT07091032 · 3,600 participants · NA
Building Connections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia